CONTINUE TO SITE
OR WAIT 15 SECS
Japan-based NEC Corporation, in collaboration with Chugai Pharmaceutical Co., has conducted an exper
AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals G
South Korea-based Mezzion Pharma Co., a leader in rare disease therapeutics, has announced the expansion of it
A research team led by Dr Der-Yang Cho, Superintendent of China Medical University Hospital (Taiwan), in colla
RevolKa Ltd., a venture-backed biotech company providing a cutting-edge artificial intelligence (AI)-driven pr
Administered through the National Health and Medical Research Council’s (NHMRC) Clinical Trials and
ForSight Robotics, an Israel-based startup in ophthalmic robotic surgery field, has completed a $125 million S
US-based Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detect
AGC Biologics will commence cell therapy process development and clinical manufacturing services on July 1, 20
Cytiva, a Danaher company and global life sciences leader, has completed significant expansion projects in sev
APAC'S ALLIANCE-DRIVEN BIOTECH BOOM
Partnerships are a cornerstone of the biotech innovation process. COVID-19 acted as a catalyst, accelerating collaboration across the sector and prompting partnerships between established players for the first time. Since then, biotech alliances have become more diverse, frequent, and strategically important, especially in the Asia-Pacific (APAC) region. Biotech partnerships of APAC differ in a variety of ways from most global collaborations, primarily due to the unique geopolitical and socio-economic landscape of the region. The region has innovation hubs like Japan and South Korea as well as large, high-growth markets such as China and India. As China rapidly scales its biopharma capabilities, it is becoming both a key market and an innovator. This transformation has redefined regional deal-making, shifting the focus from technology transfer to co-development, shared commercialisation, and strategic alignment. APAC biotech deals are no longer early-stage R&D plays, they are beginning to span the full lifecycle, from bench to bedside, including commercialisation milestones. Let’s explore further the APAC's wave of regional biotech partnerships during the first five months of this calendar year ie. from January to May 2025.
Metabolomics 2025
Metabolomics Society
info@metabolomicssociety.org https://metabolomicssociety.org/Prague
THERMAL AND ENVIRONMENTAL BARRIER COATINGS VI
ECI
eci@informz.net https://engconf.us/conferences/materials-science-including-nanotechnology/thermal-and-enviornmental-barrier-coatings-vii/Irsee, Germany
CPHI & PMEC China 2025
CCCMHPIE, Informa Markets, Sinoexpo Informa Markets
cphimarketing@imsinoexpo.com https://www.cphi.com/china/en/home.htmlShanghai New International Expo Centre (SNIEC), Shanghai, China
